Total Issue Size – Up To 60,00,000 Equity Shares of ₹ 10 each
IPO Size – ₹ 42.00 Crore (At Upper Price Band)
Price Band – ₹ 67 – ₹ 70 Per Share
Lot Size – 2,000 Equity Shares
Mumbai, January 20, 2026 ( TGN )– Hannah Joseph Hospital Limited (Hannah Joseph, The Company) a multi-specialty tertiary care hospital in Madurai with focus on Neurosciences and Trauma, proposes to open its Initial Public Offering on January 22, 2026, aiming to raise ₹ 42.00 Crore (At Upper Price Band) by fresh issue of 60,00,000 equity shares, to be listed on the BSE SME platform.
The issue size is 60,00,000 equity shares at a face value of ₹ 10 each with a price band of ₹ 67 – ₹ 70 Per Share.
Equity Share Allocation
Qualified Institutional Buyer – Not more than 28,46,000 Equity Shares
Non-Institutional Investors – Not less than 8,58,000 Equity Shares
Individual Investors – Not less than 19,96,000 Equity Shares
Market Maker – 3,00,000 Equity Shares
The net proceeds from the IPO will be utilized for Funding of capital expenditure for establishing Radiation Oncology Centre and General Corporate Purposes. The anchor portion will open on Wednesday, January 21, 2026 and the issue will open on Thursday, January 22, 2026 and will close on Tuesday, January 27, 2026.
The Book Running Lead Manager to the Issue Capital Square Advisors Private Limited, The Registrar to the Issue is Bigshare Services Private Limited.
Dr. Mosesjoseph Arunkumar, Chairman and Managing Director of Hannah Joseph Hospital Limited expressed, “Since its inception, remained committed to delivering advanced, ethical, and patient-centric healthcare services. Our evolution from a single-specialty focus to a multi-specialty tertiary care hospital reflects our continuous investments in clinical excellence, technology, and skilled medical professionals. Being a regional referral center for complex neurological, neurosurgical, cardiac, and trauma care, we have consistently strengthened our infrastructure and clinical capabilities to meet the growing healthcare needs of South Tamil Nadu.
The proposed IPO is expected to support the Company’s planned capacity and service expansion initiatives, enabling it to strengthen its clinical offerings and deliver more integrated, end-to-end care. These initiatives are aimed at enhancing patient convenience and treatment outcomes while broadening the Company’s ability to serve complex medical needs under a single platform. The expansion is also expected to drive incremental inpatient and outpatient volumes and support sustainable growth in revenues over the medium to long term.”
Mr. Sunil Kumar Manocha, Founder & Director of Capital Square Advisors Private Limited said, “Hannah Joseph Hospital operates a tertiary care facility in its core market with a focused presence across neurosciences, cardiology, trauma, and critical care. Supported by accredited operations and participation in government insurance schemes, the hospital is positioned to deploy incremental capital towards capacity enhancement and service integration initiatives.
These initiatives are expected to expand clinical offerings, improve patient throughput and case mix, and support growth in inpatient and outpatient revenues.”
About Hannah Joseph Hospital Limited:
Hannah Joseph Hospital Limited (Hannah Joseph, The Company) is a Madurai-based, Multi-Specialty Neurosciences and Trauma Center Operating 133-bed tertiary hospital with allied specialities of Cardiac Sciences, Orthopedics, Oral and Maxillofacial Surgery.
Incorporated in 2011 and transitioned into a public limited company in 2022, the hospital has developed an integrated care model supported by advanced clinical infrastructure, critical care capabilities, and academic training programs.
Led by experienced medical professionals, the Company serves as a regional referral center for complex Neurological, Neurosurgical and Trauma related surgeries while maintaining a balanced mix of inpatient and outpatient services.
For the period ended 31st March 2025, the company reported Revenue of ₹ 7,753.13 Lakhs, EBITDA Margin of 26.47% & PAT Margin 9.30%.
For the period ended 30thSeptember 2025, the company reported Revenue of ₹ 4,254.52 Lakhs, EBITDA Margin of 27.38% & PAT Margin 12.03%.
